BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Jubilant Life Sciences Ltd. has recently received the National Company Law Tribunal approval for demerger of pharma and life science ingredients (LSI) businesses into two separate companies.
We believe separate listing of both companies should happen in the next few weeks, before FY21 ends.
The company had announced this demerger in October 2019 with the rationale of two separate and focused entities for pharma and LSI segment and to unlock shareholder .
There could be some unlocking as combined entity trades at a discount to sector peers; however, we do not expect material valuation re-rating considering modest growth outlook and debt on the books.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR